BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
BrainsWay (NASDAQ: BWAY) will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 8:45 AM ET.
The presentation offers an investor-facing update; investors and analysts should contact their Needham & Co. representative to request meetings.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BWAY
On the day this news was published, BWAY gained 3.38%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BWAY fell 2.66% while only one close peer (STIM) showed downside momentum at about -3.7%; other peers had mixed, smaller moves, pointing to stock-specific factors rather than a broad medical devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | FDA-tied investment | Positive | -2.7% | Milestone-based Neurolief funding following FDA approval of ProlivRx for MDD. |
| Mar 19 | Strategic investment | Positive | +3.6% | Revenue-based milestone investment in Axis Integrated Mental Health clinics. |
| Mar 11 | Earnings and guidance | Positive | +8.3% | Strong Q4 and 2025 results with 2026 revenue and EBITDA guidance. |
| Mar 04 | Clinical data update | Positive | +7.4% | Peer-reviewed data validating SWIFT Deep TMS for faster depression treatment. |
| Feb 25 | Earnings date notice | Neutral | +0.2% | Announcement of timing for Q4 and full-year 2025 results release. |
Recent positive operational and financial updates have often coincided with upward price moves, with one notable divergence on an FDA-related investment announcement.
Over the past months, BrainsWay reported several milestones, including strong Q4 and full‑year 2025 results with guidance for 2026, and landmark clinical data for its SWIFT Deep TMS depression treatment. Strategic investments in Axis Integrated Mental Health and Neurolief, including an FDA‑tied milestone funding, highlighted expansion in mental health solutions. These events often led to positive price reactions. Today’s Needham conference appearance fits a pattern of ongoing investor outreach following a series of financial and clinical achievements since February–March 2026.
Market Pulse Summary
This announcement highlights BrainsWay’s participation in the 25th Annual Needham Virtual Healthcare Conference, signaling ongoing engagement with the investment community following several operational, clinical, and financial milestones in early 2026. Investors may focus on any incremental commentary around growth, adoption of its depression treatments, and capital allocation. Prior news on earnings, clinical data, and strategic investments provides context for how management might frame its current trajectory and priorities.
Key Terms
noninvasive neurostimulation medical
AI-generated analysis. Not financial advice.
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026.
Please contact your Needham & Co. representative to request a meeting at the conference.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
